Lamiaa El-Shennawy

Lamiaa El-Shennawy serves as a Research Assistant Professor in the Department of Pharmacology at Northwestern University's Feinberg School of Medicine. Her research integrates nanotoxicology, cancer metastasis mechanisms, and immunological responses in complex disease models.

Her primary research interests focus on nanoparticle-induced neurotoxicity, circulating tumor cell dynamics in metastasis, and immune signatures in viral infections and transplantation. Key investigations include dose-dependent effects of silver nanoparticles on neural systems, glycoprotein modifications driving chemotherapy resistance in breast cancer, and immune profiling in SARS-CoV-2-infected lung transplant recipients.

Dr. El-Shennawy's publication record demonstrates significant contributions to understanding metastatic mechanisms, particularly in triple-negative breast cancer where her work on glycoprotein hyposialylation revealed novel pathways for chemotherapy evasion. Her recent multi-omic analyses of circulating tumor cells establish critical links between molecular phenotypes and clinical outcomes.

While no formal scientific awards are documented in the provided materials, her collaborative research appears in high-impact journals including Cancer Discovery and Cell Reports Medicine. Her current work likely involves securing research grants focused on tumor metastasis and nanotoxicology, though specific funding details aren't disclosed in the profile.

Dr. El-Shennawy operates within Northwestern's pharmacology research ecosystem, contributing to interdisciplinary teams studying cancer progression and nanomaterial safety. Her recent publications suggest active collaboration with oncology, immunology, and glycobiology research groups at Feinberg.